Rovi/€ROVI
07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1Y5YMAX
About Rovi
Laboratorios Farmaceuticos ROVI SA, ticker ROVI, is a Spain-based pharmaceutical company primarily engaged in developing, manufacturing, and commercializing pharmaceutical products. The company's activities span both domestic and international markets, focusing on a range of medical and drug treatments. Founded in 1946, ROVI continues to expand its reach and influence in the healthcare and pharmaceutical sectors.
Ticker
€ROVI
Sector
Primary listing
BME
Industry
Pharmaceuticals
Headquarters
Employees
2,197
ISIN
ES0157261019
Website
Rovi Metrics
BasicAdvanced
€2.8B
20.01
€2.74
0.42
€0.89
1.38%
Price and volume
Market cap
€2.8B
Beta
0.42
52-week high
€89.50
52-week low
€45.52
Average daily volume
98K
Dividend rate
€0.89
Financial strength
Current ratio
3.705
Quick ratio
1.153
Long term debt to equity
14.224
Total debt to equity
18.08
Dividend payout ratio (TTM)
40.32%
Interest coverage (TTM)
68.52%
Profitability
EBITDA (TTM)
204.024
Gross margin (TTM)
61.56%
Net profit margin (TTM)
18.24%
Operating margin (TTM)
23.77%
Effective tax rate (TTM)
22.88%
Revenue per employee (TTM)
€350,000
Management effectiveness
Return on assets (TTM)
14.32%
Return on equity (TTM)
24.93%
Valuation
Price to earnings (TTM)
20.011
Price to revenue (TTM)
3.651
Price to book
4.75
Price to tangible book (TTM)
5.05
Price to free cash flow (TTM)
34.992
Free cash flow yield (TTM)
2.86%
Free cash flow per share (TTM)
156.55%
Dividend yield (TTM)
1.63%
Forward dividend yield
1.38%
Growth
Revenue change (TTM)
-1.49%
3-year revenue growth (CAGR)
1.98%
10-year revenue growth (CAGR)
12.27%
10-year dividend per share growth (CAGR)
18.66%
What the Analysts think about Rovi
Analyst ratings (Buy, Hold, Sell) for Rovi stock.
Bulls say / Bears say
Laboratorios Farmacéuticos Rovi has projected a significant increase in operating revenue, aiming for €1,146 million to €1,375 million by 2030, driven by the expansion of its Contract Development and Manufacturing Organization (CDMO) business. (Investing.com)
The company anticipates its CDMO revenue to reach approximately €700 million by 2030, accounting for 51% to 61% of the group's operating revenues, indicating a strategic focus on high-growth areas. (Investing.com)
ROVI expects a substantial increase in EBITDA pre-R&D, targeting 2.5x to 2.8x the FY24 figure of €233.2 million, suggesting strong profitability prospects. (Investing.com)
ROVI warned that its 2024 EBITDA is expected to be 10% to 15% lower than market consensus, primarily due to anticipated lower activity in its CDMO business during Q4. (TradingView News)
The company attributed the expected decline in CDMO activity to reduced demand for COVID-19 vaccines from Moderna, which ROVI manufactures, highlighting potential vulnerabilities in its revenue streams. (Fierce Pharma)
ROVI's exploration of selling its third-party manufacturing business, which includes a partnership with Moderna, introduces uncertainty about the company's future revenue composition and strategic direction. (Yahoo Finance)
Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2025.
Rovi Financial Performance
Revenues and expenses
Rovi Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Rovi stock?
Rovi (ROVI) has a market cap of €2.8B as of July 01, 2025.
What is the P/E ratio for Rovi stock?
The price to earnings (P/E) ratio for Rovi (ROVI) stock is 20.01 as of July 01, 2025.
Does Rovi stock pay dividends?
Yes, the Rovi (ROVI) stock pays dividends to shareholders. As of July 01, 2025, the dividend rate is €0.89399 and the yield is 1.38%. Rovi has a payout ratio of 40.32% on a trailing twelve-month basis.
When is the next Rovi dividend payment date?
The next Rovi (ROVI) dividend payment date is unconfirmed.
What is the beta indicator for Rovi?
Rovi (ROVI) has a beta rating of 0.42. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.